Aprocitentan, sold under the brand nameTryvio, is a medication used to treathypertension (high blood pressure).[1] It is developed byIdorsia.[4] It is takenby mouth.[1]
Aprocitentan isindicated for the treatment of hypertension in combination with other antihypertensive drugs, to lower blood pressure in adults who are not adequately controlled on other medications.[1]
Aprocitentan is an endothelin receptor antagonist that inhibits the protein endothelin-1 from binding to endothelin A and endothelin B receptors.[1][6] Endothelin-1 mediates various adverse effects via its receptors, such asinflammation,cell proliferation,fibrosis, andvasoconstriction.[1]
Aprocitentan was approved for medical use in the United States in March 2024.[1]
In April 2024, theCommittee for Medicinal Products for Human Use (CHMP) of theEuropean Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Jeraygo, intended for the treatment of resistant hypertension in adults.[2][10] The applicant for this medicinal product is Idorsia Pharmaceuticals Deutschland GmbH.[2] Aprocitentan was approved for medical use in the European Union in June 2024.[2][3]
^abcd"Jeraygo EPAR".European Medicines Agency. 25 April 2024.Archived from the original on 13 June 2024. Retrieved13 June 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
^ab"Jeraygo PI".Union Register of medicinal products. 28 June 2024. Retrieved5 July 2024.
Mahfooz K, Najeed S, Tun HN, Khamosh M, Grewal D, Hussain A, et al. (July 2023). "New Dual Endothelin Receptor Antagonist Aprocitentan in Hypertension: A Systematic Review and Meta-Analysis".Current Problems in Cardiology.48 (7) 101686.doi:10.1016/j.cpcardiol.2023.101686.PMID36893968.
